'What I learned from 59-year mental health career'
Rod Morris has spent 59 years working in mental health, the bulk of that time helping children and teenagers. As he finally retires, he reflects on the changes he has seen in his career, where things still need to improve and why he went back after his own near-death experience.
The summer of 1966 was a busy one for the country.
The Beatles released their album Revolver, anti-Vietnam War protests were raging and England were beating West Germany in the World Cup final at Wembley.
For 16-year-old Rod Morris it was equally momentous - he was getting a job that would last him almost six decades.
He did not have any particular desire to dedicate his life to mental health care, but his mother spotted an advert for a cadet nurse role in the local newspaper.
"My parents told me I had to get a job or move out," he recalls.
LISTEN: Rod Morris recalls 60 years of service
The role was based at St Luke's Hospital in Middlesbrough, the forerunner to the modern-day Roseberry Park Hospital, working with adults with mental health needs.
When he entered the profession, it was still the days of institutions and, in effect for many, incarceration.
Patients were kept deliberately hidden away, some for decades, a line of poplar trees planted along the front of the building to prevent people peering in.
"Every door was locked," Rod says. "There were people who had been there for years because of things like having a child out of wedlock, one woman had been there for 40 years.
"They were there for society's reasons, not because they needed to be."
But in the 1970s that all changed following major reviews, with the emphasis being shifted on to caring for people in the community.
Every other tree outside the hospital was pulled up, a symbol of the new openness that was to be encouraged, and Rod was nearing 10 years in service when he was suddenly called into his manager's office one day.
"He said to me 'right young man, you can swim, run, play football and cricket, you can start working with the teenagers," Rod says.
He suddenly found himself working with children and teenagers with mental health troubles, ultimately with the Child and Adolescent Mental Health Services (CAMHS) team at the Tees, Esk and Wear Valley Trust.
He had to adjust quickly.
"With the adults what you see is what you get, but with the young people you had to do a lot more work to break through and see what was actually going on," Rod says.
"We had all the forms and tick boxes but I found my biggest tool in my kitbag was me, the best way forward could not be found in a textbook.
"I understood kids differently.
"Many of these children had had bad experiences with authority already, I had to build a rapport with them and get them to trust me, see past the veneer to the person and what was actually driving their behaviour."
His favourite tactic was to give his young patients activities to do, keep them busy with exercise as well as offering clinical support.
"Some of them complained that I was running an outward-bound course," he says, recalling the daily football matches, camping expeditions and whatever-the-weather walks.
"I still believe activity can relate to mental health improvement," he says.
Other career highlights included a spell at a school for "troubled" girls in Newcastle and developing a course to help parents understand why their children self-harmed.
His longevity was such that he started treating the children of previous youth patients he had worked with years earlier.
He still sees some of his patients around, now in their 50s and 60s, and swaps pleasantries with them.
"I have a pretty good memory but I can't remember everyone I have seen," he says, estimating he has dealt with "thousands" of young people over five decades.
He helped develop a new team, a precursor of the modern crisis team that seeks to engage and divert those on the brink of self harm or worse.
The biggest change has been a dramatic increase in awareness, with an "explosion" of people being referred for mental health issues and conditions such as autism and ADHD leading to a backlog of diagnoses, Rod says.
"The number of people being referred has increased but staffing levels haven't," he says, adding the biggest need is for investment in more staff.
There have always been different factors affecting youth mental health, today Rod's biggest concern is social media, an issued highlighted by the Netflix series Adolescence.
"We can't not mention it," he says. "When I was at school we used to get bullied, now its on their phone.
"It's relentless."
He has been exposed to many traumas but says his enthusiasm to help people has never been hampered.
"I'm not a flamboyant character," he replies when asked how he copes with what must incredibly emotional and stressful situations.
"I think I have a typical Dutch personality in that I am very stoical and psychologically strong," he says, his mother having come from Amsterdam.
That approach helped him with his own medical emergencies.
In May 2020 Rod nearly died.
He was found collapsed at his New Marske home, an abscess on his prostate leading to sepsis and six months in hospital.
Rod returned to work but decided now was the time to retire, with the 75-year-old having seven children and 10 grandchildren to keep him busy.
He also has two new lessons learned since his own illness that he abides by.
"I have exorcised from my life anyone or anything that is negative," he says.
"And I am living for now."
Learning lessons is a lifelong endeavour and for him education is key to improving mental health care for children and young people.
"Mental health challenges in children will never go away but our responses change," he says.
"The knowledge we have has been improving massively but there is always more to learn."
A spokeswoman for the Department of Health and Social Care praised Rod as a "shining example of a career dedicated to helping others".
She said the government was making reforms to "raise the healthiest generation of children in our history" and "give mental health the same attention and focus as physical health".
That included recruiting 8,500 mental health workers, providing mental health access in schools and hubs for people aged 11 to 24, she said.
Follow BBC Tees on X, Facebook, Nextdoor and Instagram. Send your story ideas here.
Tom Grennan encourages mental health discussions
'Desperately needed' mental health hub opened
Mental health conditions are overdiagnosed, Streeting says
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gizmodo
13 hours ago
- Gizmodo
Bill Nye the Science Guy to RFK Jr: ‘Okay No More Texts'
Bill Nye, the science educator who's been a TV mainstay for decades, is not the kind of guy you'd expect would be friends with Robert F. Kennedy Jr., the most prominent anti-science kook in the country. But apparently they go way back. And Nye is getting sick of all the texts he's getting from Kennedy spouting absolute garbage. Nye met Kennedy 'many years ago,' according to a new profile of The Science Guy in Men's Health magazine, after the two men were introduced by actor Ed Begley Jr. to talk about environmental issues. Nye told the magazine that Kennedy, who's now the head of the Department of Health and Human Services, sends him endless texts. 'Just no self-awareness,' Nye said of Kennedy. 'And if you read these articles he sent, they're all this speculation about autism and just cause-and-effect, and mercury in vaccines, that maybe there's a connection.' Kennedy has long been an anti-vaccine extremist, working from 2015-2023 as chair of the Children's Health Defense. The health secretary has previously said 'there's no vaccine that is safe and effective' and has worked to limit access to vaccines, risking the lives of millions of Americans. Nye told Men's Health that he responded to the texts by saying he'd read Kennedy's book, though it's not clear which one. Kennedy has contributed to quite a few anti-science screeds, including books like Vax-Unvax: Let the Science Speak, The Wuhan Cover-Up, and 2021's The Real Anthony Fauci. That last one includes a section where Kennedy promotes 'miasma theory' and rejects germ theory. Miasma theory was abandoned in the 19th century, while the germ theory of disease is foundational to our 21st-century understanding of how diseases spread. Nye told the magazine that after he got 'miles and miles' of texts from Kennedy, he finally said, 'Okay, no more texts,' concluding Kennedy simply wasn't suited for the job he's holding in the Trump administration. Kennedy is a dangerous lunatic who doesn't even believe in germ theory. But he's going to do a lot of damage before he leaves his job. And it's already happening. Kennedy's so-called Make America Healthy Again commission issued a report last month that was riddled with errors and cited studies that don't exist. And earlier this week, Kennedy fired all 17 members of the CDC's Advisory Committee on Immunization Practices (ACIP). Those are the folks who help steer the country's vaccine policies. The FDA under Kennedy is also reportedly using AI to help approve new drugs, something that boggles the mind when you remember just how unreliable AI can be. Kennedy has repeatedly touted 'spirituality' as a fix to America's health crisis, something Trump's new pick to be Surgeon General has emphasized as well. Kennedy has long claimed that vaccines cause autism, and promised during a White House event back in April that he would reveal the 'cause' of autism by the fall. Science doesn't work with that kind of certainty or timetable, announcing the cause of a given disease like you're unveiling a new Star Wars show before the holidays. But we're not dealing with serious people, as Trump has taken charge, booting scientific experts in favor of the weirdest people on the planet. The Science Guy may try to be diplomatic when it comes to his old friend, 'Bobby' Kennedy, as he calls him in the new Men's Health article. But when even your friends are saying you don't have 'good judgment' in national magazines, something is way off.

Yahoo
18 hours ago
- Yahoo
Healthcare companies chase cures and capital in South Florida
Leaders of hundreds of public healthcare companies are in South Florida this week, talking up their innovations and financial performances to attract and impress investors at the Goldman Sachs Global Healthcare Conference. Consumers will find that nearly every disease or ailment they suffer from has a treatment in development, as big and small companies see opportunities in Americans' desire to live longer and pain-free. From new devices for sleep apnea to drugs for cancer, to creams for chronic itching and drops for improved eyesight, advances are underway that hold promise. Presenters like LENZ Therapeutics wowed the audience on Monday with product updates, such as an eyedrop that lasts all day and allows for close-up vision, which most people use reader glasses to achieve. The eye drops target a market of over 128 million people in the U.S. who need help with near vision. This year, new factors are affecting how quickly consumers can obtain a drug or device to improve or save their lives, according to company executives. The uncertainty in Washington, D.C., looms large. Policy turbulence, regulatory uncertainty, shakeups at health agencies and President Donald Trump's aggressive stance on drug pricing and tariffs factor into the future for the devices and treatments working their way toward the marketplace. Anti-Trump protests will unfold across South Florida this weekend. Here's what to expect Top RFK Jr. aide attacks US health system while running company that promotes wellness alternatives Hidden charges? Patients often face massive bills when Florida hospitals don't provide costs upfront Native Americans hurt by federal health cuts, despite RFK Jr.'s promises of protection Georgia's experience raises red flags for Medicaid work requirement moving through Congress 'This year, the biggest questions we are opening with for all of our companies is the policy calculus in Washington, D.C., and how that could play out across the healthcare sector,' said Asad Haider, Goldman Sachs' head of the healthcare business unit within Global Investment Research and the lead analyst for the U.S. pharmaceuticals sector. 'The starting point in all these presentations is give us the landscape on where things could go with respect to what's going on in Washington, D.C.' Over 200 top managerial teams attended the conference, representing every corner of the healthcare field, from major pharmaceutical companies to small biotech firms. The goal of the three-day conference was to provide institutional investors with insights into companies' business plans, data, and progress, particularly at a strategic mid-year point. Innovation hotspots this year include treatments for weight loss, with a focus on oral drugs replacing injectables and medications to help maintain a healthy weight. Another is oncology, immunology, and neuroscience with breakthroughs to detect diseases earlier and find new drug delivery methods. Several companies at the conference have formed partnerships with companies across the globe to access new markets, technologies, and expertise. China is emerging as a global leader in biotechnology, with numerous U.S. and European companies collaborating with or licensing technologies from Chinese companies. Summit Therapeutics, a Miami-based company, drew interest at the conference with its innovative cancer-fighting, bispecific antibody, ivonescimab, and its partnership with a Chinese laboratory. Ivonescimab has shown promise in previous trials in China and additional trials are underway combining the drug with chemotherapy to target non-small-cell lung cancer. 'We have over 22 or 23 different trials going on or completed or going to start,' said Maky Zangaheh, co-CEO of Summit Therapeutics. 'One element of that is a phase 3 trial that China and us are combining with over 3,000 patients enrolled, so we will have a good safety profile and efficacy profile in many different therapeutic areas. From a commercialization point of view, we are already in China and have two Chinese approvals, which is significant progress.' Doron Junger, of Sanvia Capital, a South Florida biotech investment firm, said he attended the conference looking to invest in companies developing innovations that could address large or niche markets in a more meaningful way. A few have caught his attention; however, he is cautious about those who tout therapies in their pipelines. 'More drug trials fail than succeed, and while there is a lot of innovation in this industry in areas of need like oncology and chronic diseases, even at a late stage, there is potential for a clinical trial to fail to show an advantage over a placebo group,' he said. 'Even if it does, that trial has to pass muster with the rigorous standards the FDA sets for approval.' On Monday, Arcturus Therapeutics of San Diego presented an update on a daily inhaled treatment for Cystic Fibrosis, which could be a breakthrough for the disease. Additionally, BioAge Labs CEO Kristen Fortney explained how her California company uses samples from a repository to study the biology of human aging and develop new therapies for obesity. Even after scrapping its lead obesity candidate due to liver toxicity, BioAge Labs is not shying away from the weight loss space and believes it can improve upon oral therapies now on the market, she said. 'More and more people are aging, and by definition, they are using more healthcare,' said Haider of Goldman Sachs. 'The aging population is going to need new drugs, better drugs, faster drugs for diabetes and cardiometabolics and oncology and all of these diseases that potentially could kill you. There will be innovation, but what are we willing to pay for that innovation?' Will regulations make it more difficult and/or costly for people to access the devices and drugs that can save their lives? Haider said drug pricing will be a key concern for both consumers and investors. 'Everyone is chasing big caps, big targets, but there will be winners and losers.' South Florida Sun Sentinel health reporter Cindy Goodman can be reached at cgoodman@
Yahoo
19 hours ago
- Yahoo
Memo Therapeutics AG Publishes Study in Frontiers in Pharmacology Demonstrating Therapeutic Antibody Transcytosis Across the Kidney Barrier After Intravenous Administration
Results demonstrate that intravenously administered therapeutic IgG antibodies can be detected in urine, supporting the conclusion that these antibodies are capable of crossing the kidney endothelial barrier This proof-of-concept study provides compelling support for the selected dosing regimen of MTx's investigational BK polyomavirus-neutralizing antibody Schlieren / Zurich, Switzerland, 11 June, 2025 – Memo Therapeutics AG (or 'MTx'), a late-stage biotechnology company developing antibody-based therapies for viral infections and cancer, has published a study in Frontiers in Pharmacology detailing the transport of therapeutic IgG1 antibodies across the kidney endothelial barrier. This quantitative analysis provides a scientific basis for the selected dosing strategy of MTx's highly potent human anti-BKV IgG1 therapeutic antibody, potravitug, currently in Phase II clinical development. The study reports that, 0.015% (median) of the serum concentration of therapeutic antibody rituximab is found in the urine, with levels reaching up to 4.2%. These findings suggest that therapeutic IgG antibodies can cross the kidney filtration barrier in measurable amounts, challenging prior assumptions about size-exclusion limitations and supporting the feasibility of antibody-based interventions for renal infections. Christoph Esslinger, CSO of MTx, commented: 'This data reinforces the notion that potravitug can access infected renal tissue and supports the continued development of this first-in-class candidate for the treatment of BK viremia in kidney transplant recipients.' BKV nephropathy affects up to 70% of kidney transplant recipients with established BK viremia and is associated with compromised graft function and reduced long-term graft survival. Despite this, therapeutic options remain limited, partly due to the prevailing belief that large-molecule biologics cannot effectively penetrate kidney tissue. This study contributes to a growing body of evidence suggesting otherwise. MTx is currently conducting a Phase II double-blind, randomized, placebo-controlled trial with 90 patients in the USA for the treatment of BK viremia in kidney transplant recipients, with top line results anticipated later in 2025. The full publication can be accessed here. -Ends- Contacts Memo Therapeutics AG info@ ICR Healthcare Amber Fennell, Ashley Tapp memotx@ +44 (0)20 3709 5700 About Memo Therapeutics AGMemo Therapeutics AG ('MTx') is a late-stage biotech company translating unique human immune responses into superior medicines through the development of best-in-class antibodies to treat viral infections and cancer. The Company's lead program, potravitug, is in Phase II development targeting BK viremia in kidney transplant recipients, an infection which can result in decreased kidney functionality and longevity and reduced patient survival. Potravitug has the potential to become a first-in-class BKV disease-modifying therapy for kidney transplant patients with a market potential of up to $2bn. Alongside potravitug, MTx is focused on discovering novel oncology targets. Underpinning MTx's core assets is its proprietary DROPZYLLA® technology, an antibody repertoire copying engine with high-throughput screening capabilities. MTx is a private company located in Schlieren / Zurich and backed by investors including Ysios Capital, Kurma Partners, Pureos Bioventures, Swisscanto, Vesalius Biocapital and Adjuvant Capital. Learn more at and on in to access your portfolio